Study design and participants
osteosarcoma, ASPS
ONCOLOGY, OSTEOSARCOMA
In this nonrandomized, multicenter, phase IB study (dose-expansion part), we included adult patients (age ≥ 18 years) with histologically proven advanced osteosarcoma (having undergone at least two lines of systemic therapy) or ASPS; an Eastern Cooperative Oncology Group performance status [